These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 19257823)

  • 1. One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength.
    Ominsky MS; Stolina M; Li X; Corbin TJ; Asuncion FJ; Barrero M; Niu QT; Dwyer D; Adamu S; Warmington KS; Grisanti M; Tan HL; Ke HZ; Simonet WS; Kostenuik PJ
    J Bone Miner Res; 2009 Jul; 24(7):1234-46. PubMed ID: 19257823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.
    Ominsky MS; Li X; Asuncion FJ; Barrero M; Warmington KS; Dwyer D; Stolina M; Geng Z; Grisanti M; Tan HL; Corbin T; McCabe J; Simonet WS; Ke HZ; Kostenuik PJ
    J Bone Miner Res; 2008 May; 23(5):672-82. PubMed ID: 18433301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HLA-B27 transgenic rat, a model of spondyloarthritis, has decreased bone mineral density and increased RANKL to osteoprotegerin mRNA ratio.
    Rauner M; Stupphann D; Haas M; Fert I; Glatigny S; Sipos W; Breban M; Pietschmann P
    J Rheumatol; 2009 Jan; 36(1):120-6. PubMed ID: 19040304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status.
    Fahrleitner A; Prenner G; Kniepeiss D; Iberer F; Tscheliessnigg KH; Piswanger-Sölkner C; Obermayer-Pietsch B; Leb G; Dobnig H
    Wien Klin Wochenschr; 2002 Aug; 114(15-16):717-24. PubMed ID: 12602117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength.
    Ulrich-Vinther M; Andreassen TT
    Calcif Tissue Int; 2005 Apr; 76(4):280-6. PubMed ID: 15812581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
    Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
    Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
    Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation.
    Ricci P; Tauchmanova L; Risitano AM; Carella C; Mazziotti G; Lombardi G; Colao A; Rotoli B; Selleri C
    Transplantation; 2006 Dec; 82(11):1449-56. PubMed ID: 17164716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone density, strength, and formation in adult cathepsin K (-/-) mice.
    Pennypacker B; Shea M; Liu Q; Masarachia P; Saftig P; Rodan S; Rodan G; Kimmel D
    Bone; 2009 Feb; 44(2):199-207. PubMed ID: 18845279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.
    Baek KH; Oh KW; Lee WY; Tae HJ; Rhee EJ; Han JH; Cha BY; Kim YJ; Lee KW; Son HY; Kang SK; Kim CC; Kang MI
    Bone; 2006 Dec; 39(6):1352-60. PubMed ID: 16905375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice.
    Samadfam R; Xia Q; Goltzman D
    J Bone Miner Res; 2007 Jan; 22(1):55-63. PubMed ID: 17014384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio.
    Seriwatanachai D; Thongchote K; Charoenphandhu N; Pandaranandaka J; Tudpor K; Teerapornpuntakit J; Suthiphongchai T; Krishnamra N
    Bone; 2008 Mar; 42(3):535-46. PubMed ID: 18166509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
    Cao J; Venton L; Sakata T; Halloran BP
    J Bone Miner Res; 2003 Feb; 18(2):270-7. PubMed ID: 12568404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin reduces the loss of periarticular bone mass in primary and secondary spongiosa but does not influence inflammation in rat antigen-induced arthritis.
    Neumann T; Oelzner P; Petrow PK; Thoss K; Hein G; Stein G; Bräuer R
    Inflamm Res; 2006 Jan; 55(1):32-9. PubMed ID: 16429254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
    Monegal A; Navasa M; Peris P; Alvarez L; Pons F; Rodés J; Guañabens N
    Liver Int; 2007 May; 27(4):492-7. PubMed ID: 17403189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.
    Kostenuik PJ; Bolon B; Morony S; Daris M; Geng Z; Carter C; Sheng J
    Bone; 2004 Apr; 34(4):656-64. PubMed ID: 15050896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
    Koyama H; Nakade O; Takada Y; Kaku T; Lau KH
    J Bone Miner Res; 2002 Jul; 17(7):1219-29. PubMed ID: 12096835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses.
    Stolina M; Dwyer D; Ominsky MS; Corbin T; Van G; Bolon B; Sarosi I; McCabe J; Zack DJ; Kostenuik P
    J Immunol; 2007 Dec; 179(11):7497-505. PubMed ID: 18025194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.